Prostate Cancer | China In-Depth | 2024
The treatment of prostate cancer in China is undergoing a transformative phase, characterized by an increase in diagnosed incident cases due to improved screening techniques. This shift is accompanied by a late-phase pipeline that includes next-generation hormonal agent such as Hinova Pharmaceuticals’ HC-1119 and premium-priced PARP inhibitors such as Pfizer’s talazoparib, AstraZeneca’s saruparib, and Johnson & Johnson Innovative Medicine’s Akeega. The sustained uptake of second-generation hormonal therapies, owing to their label expansions, further contributes to the evolving treatment paradigm. In this report, we assess how clinical and nonclinical factors—price dynamics, inclusion in China’s National Reimbursement Drug List (NRDL)—will influence the launch and uptake of new therapies during the forecast period. Understanding the impact of these intersecting factors will be key to the success of current and future players in this highly lucrative market.
Questions answered
- How large is China’s drug-treatable prostate cancer population, and how will drug-treatment rates change during the forecast period?
- What are interviewed experts’ insights into current treatments?
- What are the key unmet needs in the management of prostate cancer?
- What are the key market access considerations, and how are they likely to impact the uptake of emerging therapies in this market?
- What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?
Product description
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
NEW: China In-Depth reports include a custom drug modeler. This tool enables clients to input their own assumptions for a drug and forecast three scenarios that can be directly compared with Clarivate’s projections for drugs included in the patient-based market forecast. To access the tool, download the Market Forecast Dashboard file on the Insights Platform.
